-PTI New Delhi: The drug price regulator has sought details of patented medicines as part of a drive to fix their rates. The National Pharmaceutical Pricing Authority (NPPA) is also fixing the price ceiling for 102 drugs on the National List of Essential Medicines (NLEM) and has asked for financial data, like retail rates and the firms' turnover. On patented drugs imported or manufactured for sale in India, the NPPA has called for...

-The Times of India The union health ministry's target of distributing 50 drugs free under the free essential drug scheme is so much lower than the hundreds of drugs being provided by states with a functioning free drugs scheme that it has left health officials in these states puzzled. After starting off by talking of distributing 348 drugs in the National List of Essential Medicines (NLEM) during the tenure of Dr Harsh...

-Economic and Political Weekly The key to improving the quality of healthcare services in India and reducing costs at the same time can be found by enacting legislation which lays down minimum standards of patient care. In the absence of such standards and the reluctance of health insurance companies to standardise either price or quality, healthcare services continue to be expensive and of doubtful quality. Developing standards of patient care by...

-Business Standard This would be in addition to 348 drugs already under price ceiling The National Pharmaceutical Pricing Authority (NPPA) has capped the prices of another 52 essential drugs, in a move that could impact drug manufacturers Lupin, Cadila Healthcare and Merck. This is in addition to the 348 drugs already under a price ceiling. The majority of the 52 new drugs are antibiotics, painkillers and medicines used for treating cancer and skin...

-The Times of India NEW DELHI: The drug price regulator has mandated companies to seek its approval for every new medicine, including combinations of existing ones, to ensure that consumers are not overcharged. According to the National Pharmaceutical Pricing Authority (NPPA) all innovative launches like new combinations of price-controlled medicines as well as those with changed strengths and dosages will be treated as 'new medicines'. The move is aimed at spanning the...